TRDA logo

ENTRADA THERAPEUTICS INC

TRDANASDAQ
🏆 #3705 by market capUS Equity
$4.39▼ $0.44 (−9.20%)
After hours · at close
🔔
Track TRDA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 9.2%
7d▼ 7.3%
14d▼ 8.0%
30d▼ 30.0%
ytd▼ 57.3%
1y▼ 35.9%
🏦Market Cap
$171M
Small Cap
📈Revenue Growth (YoY)
-87.9%
Declining
📊Gross Margin
-754.7%
Thin
💵FCF Margin
-2867.1%
Thin
⚖️P/S Ratio
36.6x
Expensive
Otter Score
40
Weak

Trading Snapshot

Day Range
$4.35 – $4.96
52-Week Range
$4.11 – $16.45
Volume (shares)
36,771
Avg Volume (shares)
—
Shares Outstanding
38.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$25M
Last Q Revenue
$898,000
P/E Ratio
-1.1
P/S Ratio
36.6x
EPS (TTM)
$-3.93
Dividend Yield
0.00%
Dilution (1yr)
−3.9%
TRDA logo

ENTRADA THERAPEUTICS INC

TRDA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$25M▼ −87.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.9%▼ −16.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$156M▼ −431.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$130M▲ +189.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41.4M▼ −3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$39M▼ −$3M YoY
StockOtter · stockotter.space

About ENTRADA THERAPEUTICS INC

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100
Analyst data unavailable.

Latest News & Updates

News unavailable.